Secretion of leukaemia inhibitory factor after allogeneic bone marrow transplantation: a study of CD4+ and CD8+ TCR alpha beta+ T-cell clones derived from four leukaemia patients.
CD4+ and CD8+ TCR alpha beta+ T-cell clones were derived from 4 leukaemia patients early (4-6 weeks) after allogeneic bone marrow transplantation. Leukemia inhibitory factor (LIF) secretion in response to the activation signal accessory cells (AC) + phytohaemagglutinin (PHA) was investigated for each individual clone. Only a minority of CD4+ TCR alpha beta+ T-cell clones secreted LIF in response to AC + PHA, whereas most T-cell clones were capable of LIF secretion when exogenous interleukin 2 was added together with AC + PHA. LIF secretion could also be demonstrated for CD8+ TCR alpha beta+ posttransplant T-cell clones. Thus, posttransplant CD4+ and CD8+ TCR alpha beta+ clonogenic T-cells are capable of LIF secretion, and LIF secretion may be a T-cell effector mechanism in graft versus host disease, graft versus leukaemia effects or posttransplant haematopoietic reconstitution.
Bruserud
O
O
Second Department of Internal Medicine, Tubingen University Medical Clinic, FRG.
Hamann
W
W
Pawelec
G
G
D016026:Bone Marrow Transplantation; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism*; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D002478:Cells, Cultured; D002999:Clone Cells; D006131:Growth Inhibitors / Q000096:biosynthesis*; D006801:Humans; D015850:Interleukin-6; D007938:Leukemia / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000096:biosynthesis*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000096:biosynthesis*; D013601:T-Lymphocytes / Q000378:metabolism* / Q000473:pathology; D014184:Transplantation, Homologous
D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D016693:Receptors, Antigen, T-Cell, alpha-beta